Results 181 to 190 of about 265,465 (283)

A literature review of finding the associated risks for developing deep vein thrombosis using peripherally inserted central catheters (PICC) with vascular ultrasound [PDF]

open access: yes
Objective: Peripherally inserted central catheters (PICC) lines are becoming more widely used in hospitalization for usage of chemotherapy, blood transfusion, and accessibility through the upper extremity venous system.
Uyehara, Craig
core   +1 more source

Current and novel biomarkers in cardiogenic shock

open access: yesEuropean Journal of Heart Failure, EarlyView.
A summary of current and novel biomarkers and their potential stages of release in cardiogenic shock. The diagram illustrates the proposed release of the biomarkers during the different stages of cardiogenic shock: progression from cardiac dysfunction/stress, through to inflammation and end‐organ dysfunction.
Victor Galusko   +5 more
wiley   +1 more source

Melioidosis with venous thrombosis and cellulitis in the left lower limb: a case report. [PDF]

open access: yesJ Med Case Rep
Palit A   +11 more
europepmc   +1 more source

Lower extremity lymphatic flow is associated with diuretic response in acute heart failure

open access: yesEuropean Journal of Heart Failure, EarlyView.
Lower extremity lymphatic flow and diuretic response in acute heart failure (AHF). IV, intravenous. (Created in BioRender) Abstract AimsThe dysfunctional lymphatic system appears to play an important role in the development and progression of congestion in heart failure. We hypothesized that in acute heart failure (AHF), diuretic efficacy is associated
Barbara Ponikowska   +6 more
wiley   +1 more source

Ten‐year follow‐up of a case of eosinophilic granulomatous with polyangiitis

open access: yes
ESC Heart Failure, EarlyView.
Jiange Qiao   +6 more
wiley   +1 more source

Portomesenteric Venous Thrombosis Presenting as Bowel Gangrene. [PDF]

open access: yesCureus
Khalifa S   +4 more
europepmc   +1 more source

Interim analysis of the long‐term efficacy and safety of azetukalner in an ongoing open‐label extension study following a phase 2b clinical trial (X‐TOLE) in adults with focal epilepsy

open access: yesEpilepsia Open, EarlyView.
Abstract Objective To report interim data from an ongoing, open‐label extension (OLE) of a Phase 2b study (X‐TOLE) of azetukalner in adults with focal onset seizures (FOS) receiving 1–3 antiseizure medications. Methods Eligible participants enrolled in the 7‐year OLE at 20 mg azetukalner once daily with food.
Jacqueline A. French   +62 more
wiley   +1 more source

Home - About - Disclaimer - Privacy